Arrowhead Pharmaceuticals has released positive interim results from its Phase 1/2 study of its investigational therapeutic ARO-RAGE for inflammatory lung diseases such as asthma, sending its share price higher by more than 15%.
Arrowhead’s ARO-RAGE is an RNA interference (RNAi) therapeutic designed to reduce the production of the receptor of advanced glycation end products as a possible treatment for inflammatory pulmonary diseases, Arrowhead said.
It reported on Tuesday that interim results from the Phase 1/2 study demonstrated up to 90% reduction in soluble RAGE (sRAGE) as measured in serum with a mean maximum reduction of 80% after two doses.
The data also demonstrated the potential use of Arrowhead’s Targeted RNAi Molecule (TRiM) platform for optimized delivery to the lungs, according to the company.
"We think these interim data with ARO-RAGE represent clinical validation of Arrowhead’s inhaled pulmonary TRiM platform and, specifically, of ARO-RAGE as a potential new therapy to treat patients with inflammatory lung diseases,” commented Arrowhead CEO Dr Christopher Anzalone in a statement.
“The high level of target gene knockdown, the long duration of effect, and the promising safety and tolerability results are all very encouraging signs for our growing pipeline of RNAi therapeutic candidates that leverage this same platform.”
Arrowhead stock was up 17.8% at US$35.35 on Tuesday morning.
Contact the author at [email protected]
Follow her on Twitter @emilyjjarvie